NASDAQ · TRML
Tourmaline Bio, Inc.
$47.98$0.00 (0.0%)
Tourmaline Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.6% below the high.
Loading market information…
NASDAQ · SCTL · USD
Stock price, earnings
Quote as of Apr 5, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Societal CDMO, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.06% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Societal CDMO, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Societal CDMO, Inc., an organization founded in Exton, Pennsylvania, in 2007, functions as a contract development and manufacturing partner for the global pharmaceutical industry. Formerly known as Recro Pharma, Inc. until its name change in March 2022, the company specializes in supporting small molecule therapeutic advancements. Its comprehensive services span the entire drug development lifecycle, from initial research and development to manufacturing and packaging various therapeutic dosage forms for both domestic and international markets. Key offerings include drug development expertise, end-to-end regulatory guidance, clinical and commercial scale production, sterile fill/finish operations, freeze-drying (lyophilization), and integrated packaging and logistics solutions.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:46 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2022 | Nov 9, 2022 | -$0.060.0% vs estimate | $21.59M+0.73% vs estimate |
|---|
| Q2 2022 | Aug 10, 2022 | -$0.06+25.0% vs estimate | $23.15M+13.92% vs estimate |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$47.98$0.00 (0.0%)
Tourmaline Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.6% below the high.
$0.63+$0.04 (+7.29%)
Sesen Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.84% below the high.
$4.91-$0.04 (-0.81%)
Decibel Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 9.07% below the high.
$5.50-$0.67 (-10.8%)
Graybug Vision, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.91% below the high.
$2.35-$0.01 (-0.21%)
Augmedix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.48% below the high.
$20.65$0.00 (0.0%)
Opiant Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.52% below the high.
$3.02-$0.07 (-2.27%)
Cyteir Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.33% below the high.
$1.01+$1.01 (+100.0%)
Procaps Group S.A.’s quoted price sits in the lower half of its reported 52-week range, 73.25% below the high.
